Bausch + Lomb rises on FDA approval of lenses for cataract surgery

Bausch + Lomb

14/10/2024 16:31

** U.S.-listed shares of Bausch + Lomb  BLCO.TO  up about 8%
at $21
    ** The eye care firm is exploring a sale, with TPG and
Blackstone teaming up to bid for co, the Financial Times
reports.
    ** Company declines to comment
    ** Separately, co gets U.S. FDA approval for enVista Envy
Full Range of Vision Intraocular Lens (IOL)
    ** IOL are lenses that restore vision lost to cataracts and
to fix other visual errors like nearsightedness or
farsightedness
    ** Co says the lens will be available in the U.S. shortly
and more broadly in 2025. 
    ** Including session's gains, stock up ~14% YTD

    
  

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))